I-Mab to Participate at the Truist Securities BioPharma Symposium
Werte in diesem Artikel
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
Meeting Date | Thursday, November 7, 2024 |
Meetings | One-on-one and small group meetings: November 7, 2024 |
Management | Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html
SOURCE I-Mab Biopharma
Ausgewählte Hebelprodukte auf I-MAB (spons. ADRs)
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf I-MAB (spons. ADRs)
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu I-MAB (spons. ADRs)
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu I-MAB (spons. ADRs)
Keine Analysen gefunden.